En la antesala de su salida bursátil, SpaceX fija precio de la acción a US$ 135 y levanta cifra récord de US$ 75 mil millones Ivar AI

The Times of India

US stocks: SpaceX to make historic listing on Nasdaq on Friday that could make Elon Musk a trillionaire

BusinessLine

SpaceX IPO pushes Elon Musk’s net worth past $1 trillion

N-tv.de

Nach Hubschrauber-Abschuss: "Selbstverteidigung": US-Militär fliegt neue Angriffe gegen den Iran

Crypto Briefing

US Army helicopter shot down by Iran near Strait of Hormuz, Trump confirms

POLITICO.eu

US launches a second straight day of airstrikes in Iran

The Daily Caller

China Pours More Fuel On The AI Arms Race Fire

Diariobitcoin.com

DEXE desafía la gravedad con un alza del 4.24% mientras la fiebre de los DAOs se intensifica el 11 de junio de 2026

New York Post

Meta and Mike Rowe launch $115 trade-training program that guarantees jobs to future welders, plumbers, electricians

The Times of India

US stocks: Oppenheimer launches Wall Street's first coverage of SpaceX with bullish outlook

Diariobitcoin.com

Audiera ($BEAT) desafía la gravedad: ¿burbuja o nuevo paradigma cripto?

Crypto Briefing

Iran targets US ships near Strait of Hormuz with missiles and drones

Crypto Briefing

IRGC Navy strikes two oil tankers in Strait of Hormuz, escalating crisis at world’s most critical oil chokepoint

Yahoo Entertainment

美科技巨頭 IPO 潮達 3.6 兆美元 SpaceX 募資恐吸走加密市場資金

Yahoo Entertainment

美國通膨創高推升升息預期黃金連兩日重挫

BBC News

Live: US striking Iran in response to downing of helicopter, military says

Crypto Briefing

Trump says Iran deal ‘very close,’ could impact troop withdrawal

Crypto Briefing

US fires 49 Tomahawk missiles at Iran in major escalation

Diariobitcoin.com

Bancos apuestan por combinar stablecoins, depósitos tokenizados y fondos digitales en una sola infraestructura

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire